SS-31 and NMN: Two paths to improve metabolism and function in aged hearts by Whitson, Jeremy A et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
10-1-2020 
SS-31 and NMN: Two paths to improve metabolism and function 
in aged hearts 
Jeremy A Whitson 
Alessandro Bitto 
Huiliang Zhang 
Mariya T Sweetwyne 
Rene Coig 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
Authors 
Jeremy A Whitson, Alessandro Bitto, Huiliang Zhang, Mariya T Sweetwyne, Rene Coig, Saakshi Bhayana, 
Eric G Shankland, Lu Wang, Theo K Bammler, Kathryn F Mills, Shin-Ichiro Imai, Kevin E Conley, David J 
Marcinek, and Peter S Rabinovitch 
Aging Cell. 2020;19:e13213.	 	 	 | 1 of 14
https://doi.org/10.1111/acel.13213
wileyonlinelibrary.com/journal/acel
Received:	20	March	2020  | Revised:	16	June	2020  | Accepted:	13	July	2020
DOI: 10.1111/acel.13213  
O R I G I N A L  A R T I C L E
SS-31 and NMN: Two paths to improve metabolism and 
function in aged hearts
Jeremy A. Whitson1  |   Alessandro Bitto1 |   Huiliang Zhang1 |   Mariya T. Sweetwyne1 |   
Rene Coig1 |   Saakshi Bhayana2 |   Eric G. Shankland2 |   Lu Wang3 |   Theo K. Bammler3 |   
Kathryn F. Mills4 |   Shin-Ichiro Imai4 |   Kevin E. Conley2 |   David J. Marcinek2 |    
Peter S. Rabinovitch1
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution	License,	which	permits	use,	distribution	and	reproduction	in	any	medium,	
provided the original work is properly cited.
©	2020	The	Authors.	Aging Cell	published	by	Anatomical	Society	and	John	Wiley	&	Sons	Ltd
1Department	of	Laboratory	Medicine	and	
Pathology,	University	of	Washington,	
Seattle,	Washington
2Department	of	Radiology,	University	of	
Washington,	Seattle,	Washington
3Department	of	Environmental	&	
Occupational	Health	Sciences,	University	
of	Washington,	Seattle,	Washington
4Department	of	Developmental	Biology,	
Washington	University	School	of	
Medicine,	St.	Louis,	Missouri
Correspondence
Peter	S.	Rabinovitch,	1959	NE	Pacific	St,	
HSB	K-081,	Seattle,	WA	98195.
Email: petersr@u.washington.edu
Funding information
Funding for this research was provided 
by	the	UW	Genetic	Approaches	to	
Aging	Training	Grant	T32AG000057-40,	
P01AG001751	grant,	and	the	UW	Nathan	
Shock	Center,	and	AFAR	Glenn	Foundation	
for Medical Research Postdoctoral 
Fellowship	for	Aging	Research	and	AHA	
19CDA34660311	to	HZ.	SS-31	was	
provided	by	Stealth	BioTherapeutics	
(Newton,	MA)	free	of	charge.	Stealth	
BioTherapeutics did not play any role in 
the	funding,	experimental	design,	data	
collection,	or	authorship	of	this	research.
Abstract
The	 effects	 of	 two	 different	 mitochondrial-targeted	 drugs,	 SS-31	 and	 NMN,	 were	
tested	on	Old	mouse	hearts.	After	treatment	with	the	drugs,	individually	or	Combined,	
heart	function	was	examined	by	echocardiography.	SS-31	partially	reversed	an	age-re-
lated	decline	in	diastolic	function	while	NMN	fully	reversed	an	age-related	deficiency	
in systolic function at a higher workload. Metabolomic analysis revealed that both 
NMN	and	the	Combined	treatment	increased	nicotinamide	and	1-methylnicotinamide	
levels,	 indicating	greater	NAD+	 turnover,	but	only	the	Combined	treatment	resulted	
in	significantly	greater	steady-state	NAD(H)	levels.	A	novel	magnetic	resonance	spec-
troscopy approach was used to assess how metabolite levels responded to chang-
ing	cardiac	workload.	PCr/ATP	decreased	 in	 response	 to	 increased	workload	 in	Old	
Control,	but	not	Young,	hearts,	indicating	an	age-related	decline	in	energetic	capacity.	
Both	drugs	were	able	to	normalize	the	PCr/ATP	dynamics.	SS-31	and	NMN	treatment	
also	 increased	mitochondrial	NAD(P)H	production	under	the	higher	workload,	while	
only	NMN	 increased	NAD+ in response to increased work. These measures did not 
shift	 in	hearts	given	the	Combined	treatment,	which	may	be	owed	to	the	enhanced	
NAD(H)	levels	in	the	resting	state	after	this	treatment.	Overall,	these	results	indicate	
that both drugs are effective at restoring different aspects of mitochondrial and heart 
health and that combining them results in a synergistic effect that rejuvenates Old 
hearts	and	best	recapitulates	the	Young	state.
K E Y W O R D S
aging,	heart,	magnetic	resonance	spectroscopy,	metabolomics,	NMN,	SS-31
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1  |  INTRODUC TION
Cardiovascular disease remains the major cause of mortality in older 
adults	 (Heron	&	Anderson,	2016;	Tinetti	et	al.,	2012),	eclipsing	all	
forms	of	cancer	by	the	age	of	75	(Roger	et	al.,	2011).	Furthermore,	
age-related	decline	in	heart	function,	which	includes	dysfunction	in	
both	diastole	and	systole	(Dai,	Chen,	Johnson,	Szeto,	&	Rabinovitch,	
2012),	 has	 been	 shown	 to	 be	 strongly	 associated	 with	 frailty	
(Leibowitz	 et	 al.,	 2016).	 Because	 of	 the	 immense	 burden	 of	 heart	
dysfunction	 on	 the	 elderly	 population,	 the	 development	 of	 treat-
ments that can improve heart health in aged individuals remain a top 
priority	for	extending	human	healthspan.
The majority of the heart's volume consists of cardiomyocytes 
(Zhou	&	Pu,	 2016),	which	must	meet	 the	 incredible	 energetic	 de-
mand	of	continuous	contraction	and	 relaxation	 throughout	an	en-
tire	 lifespan.	To	meet	 this	 energetic	need,	heart	 tissue	has	one	of	
the	highest	mitochondrial	densities	found	in	the	body	(Benard	et	al.,	
2006).	 As	 cells	 age,	 nicotinamide	 dinucleotide	 (NAD+)	 levels,	 ATP	
output,	 and	 mitochondrial	 biogenesis	 decrease,	 while	 oxidative	
stress,	 mtDNA	 damage,	 and	 mitochondrial	 structural	 alterations	
increase	(Chistiakov,	Sobenin,	Revin,	Orekhov,	&	Bobryshev,	2014).	
Based	 on	 these	 physiological	 features,	 it	 has	 long	 been	 hypothe-
sized that mitochondrial fitness is key to maintaining heart health 
(Herrmann	&	Decherd,	 1939).	 According	 to	 this	 hypothesis,	 treat-
ments that can restore mitochondrial parameters to more youthful 
states in aged cardiomyocytes have the potential to repair the func-
tion of aged hearts.
In	this	study,	we	set	out	to	determine	the	functional	and	meta-
bolic	effects	on	aged	mouse	hearts	of	 two	mitochondrial-targeted	
drugs	proposed	to	treat	age-related	dysfunction:	SS-31	and	nicotin-
amide	mononucleotide	(NMN).
SS-31,	also	known	as	elamipretide,	 is	a	synthetic	tetrapeptide	
consisting	of	D-arginine,	2′,6′-dimethyl-l-tyrosine,	lysine,	and	phe-
nylalanine	that	associates	with	the	head	group	of	cardiolipin,	an	es-
sential phospholipid specific to the mitochondrial inner membrane 
(Szeto,	2014).	Previous	testing	of	SS-31	in	mammals	has	shown	that	
the	drug	decreases	oxidative	stress	(Hou	et	al.,	2016)	and	protects	
against	ischemia–reperfusion	injury	(Cai	et	al.,	2018),	although	the	
specific mechanisms by which the drug elicits these changes are 
still being actively investigated. There are indications that a combi-
nation	of	preventing	cytochrome	c	peroxidase	activity,	promoting	
cristae,	and	electron	transport	chain	complex	organization,	as	well	
as	 influencing	 other	mitochondrial	 proteins,	 contributes	 to	 these	
beneficial	 effects	 (Birk,	 Chao,	 Bracken,	 Warren,	 &	 Szeto,	 2014;	
Szeto,	2014).	We	have	recently	demonstrated	that	SS-31	improves	
diastolic	function	and	reduces	oxidative	stress	in	the	hearts	of	aged	
mice	when	delivered	for	8	weeks	(Chiao	et	al.,	2020).
NMN	is	a	naturally	occurring	nucleotide	precursor	of	NAD+ that 
is	generated	via	the	NAD+	salvage	pathway	(Yoshino,	Baur,	&	Imai,	
2018).	NMN	and	its	precursor	nicotinamide	riboside	(NR)	have	been	
hypothesized to improve mitochondrial health by increasing cellular 
NAD+ availability and therefore improving energetic capacity and 
activating sirtuin deacetylase activity. Recent studies have provided 
strong	evidence	 for	 this	hypothesis	 and	 shown	 that	NMN	supple-
mentation	 bolsters	NAD+ availability and improves many classical 
signs	of	aging	in	mice	(Mills	et	al.,	2016).	NMN	supplementation	has	
also been shown to partially restore heart function in a mouse model 
of	heart	failure	(Lee	et	al.,	2016).
Although	NMN	and	SS-31	both	target	mitochondria,	they	do	so	
via	different	mechanisms	of	action.	Thus,	we	hypothesized	that	the	
drugs would differ in effect on the heart and may have a synergistic 
effect	when	applied	together.	We	sought	to	compare	and	contrast	
the mechanism and effects of these drugs in order to better under-
stand	each	individually	and	how	age-related	deficits	 in	heart	func-
tion can be addressed.
Because mice recapitulate many aspects of human aging 
(Vanhooren	 &	 Libert,	 2013),	 including	 a	 general	 decline	 in	 heart	
function	 (Dai	 et	 al.,	 2012),	 they	 are	 an	 excellent	model	 for	 deter-
mining whether these drugs have the potential to rejuvenate aged 
hearts in humans and to determine the mechanisms of this im-
provement.	 To	 test	 the	 effects	 of	 these	 drugs	 on	 the	 aged	 heart,	
mice	aged	24	months	at	the	start	of	treatment	(Old)	were	randomly	
sorted	into	Control,	SS-31,	NMN,	or	Combined	(SS-31	+	NMN)	treat-
ment	groups	for	comparison	with	mice	5–6	months	of	age	(Young).	
Treatment	doses	of	SS-31	and	NMN	were	in	alignment	with	those	
that have previously been shown to be effective in other healthspan 
measures	(Chiao	et	al.,	2020;	Mills	et	al.,	2016).	In	vivo	magnetic	res-
onance	spectroscopy	is	typically	used	to	examine	ATP	and	PCr	levels	
in	muscle	tissue,	though	when	applied	to	beating	hearts	the	spectra	
must	be	voxel-localized	and	timed	to	coincide	with	heart	and	pulmo-
nary	cycles.	In	this	report,	we	further	developed	and	applied	for	the	
first	time	an	MRS	technique	to	determine	how	additional	heart	me-
tabolites,	including	nicotinamide	nucleotides,	respond	to	an	increase	
in	 cardiac	workload,	defined	by	an	accelerated	heart	 rate,	 in	vivo.	
This analysis was coupled with measurements by echocardiography 
and	liquid	chromatography	tandem	mass	spectrometry	(LC-MS/MS)	
to obtain an integrated view of changes resulting from age and drug 
treatment from the metabolic to the functional level in the heart.
2  |  RESULTS
2.1  |  SS-31 and NMN treatments result in different 
functional improvements
Echocardiography was performed on all mice at baseline and again 
on	Old	mice	after	8	weeks	of	treatment.	Diastolic	function	was	as-
sessed by determining the ratio of blood flow across the mitral valve 
in	early	diastole	(Ea)	to	the	flow	in	late	diastole	(Aa).	Ea/Aa	is	one	of	
the primary markers used when assessing diastolic function in human 
patients	(Mitter,	Shah,	&	Thomas,	2017)	and	is	the	parameter	of	di-
astolic function that has been used in composing a comprehensive 
frailty	index	of	mouse	aging	(Kane,	Keller,	Heinze-Milne,	Grandy,	&	
Howlett,	2019).	Old	Control	mice	had	a	significantly	(p	<	0.05)	lower	
Ea/Aa	 compared	 to	 Young	mice	 at	 their	 baseline,	 indicating	 a	 de-
cline	in	diastolic	function	with	age.	As	found	previously	(Chiao	et	al.,	
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2020),	Old	mice	treated	with	SS-31	showed	a	significant	(p	<	0.05)	
improvement	in	Ea/Aa,	restoring	it	approximately	halfway	to	that	of	
Young	Ea/Aa	values,	whereas	the	Control	and	NMN-treated	groups	
showed	 no	 change	 in	 this	 parameter	 (Figure	 1a).	 The	 Combined	
treatment	 group	 recapitulated	 the	 Ea/Aa	 change	 resulting	 from	
SS-31	alone	but	did	not	show	any	further	improvement.
Systolic	function	was	assessed	by	measuring	percent	fractional	
shortening	 (i.e.,	 the	 degree	 to	which	 the	 ventricular	 lumen	 closes	
during	systole)	from	echocardiograms.	Since	anesthetized	mice	have	
subphysiological	heart	rates,	alterations	in	systolic	function	may	not	
be	 manifested	 under	 these	 low	 work	 conditions.	 Thus,	 fractional	
shortening was also measured following injection of the ionotropic 
agent dobutamine at a concentration that produced higher heart 
rates	within	 the	normal	physiological	 range	 (Figure	1b).	Long-term	
assessment of heart rates showed that dobutamine administra-
tion results in a similar significant (p	<	0.001)	increase	in	heart	rate	
across	all	groups	(Figure	S1).	There	were	no	significant	differences	
in fractional shortening between the groups at the low work state 
or within groups at treatment endpoints relative to their baselines 
(Figure	S2).	Under	higher	workload	conditions,	however,	Old	Control	
mice manifested a significantly (p	<	0.0001)	lower	percent	fractional	
shortening	than	Young	mice,	 indicating	a	decline	 in	high	work	sys-
tolic	function	with	age.	SS-31	treatment	did	not	significantly	affect	
fractional	shortening,	but	NMN	and	the	Combined	treatments	both	
F I G U R E  1   Effect	of	SS-31	and	NMN	on	heart	function.	(a)	Ea/Aa	ratio	at	baseline	(treatment	day	0)	and	endpoint	(8	weeks	of	treatment)	
and	(b)	percent	fractional	shortening	at	low	work	(-dobutamine)	and	high	work	(+dobutamine)	at	the	8	week	treatment	endpoint,	measured	
by echocardiography. N	=	29	Young,	49	Old	Control,	29	Old	SS-31,	28	Old	NMN,	10	Old	Combined.	(c)	High	work	(+dobutamine)	percent	
fractional	shortening	measured	by	echocardiography	in	Young	and	Old	mice	at	0,	1,	6,	10,	20,	30,	42,	and	56	days	of	NMN	treatment.	
N	=	8	Young,	19	Old.	(d)	Ratio	of	heart	weight	(g)	to	tibia	length	(mm)	assessed	at	endpoint	(8	weeks	of	treatment)	as	a	measure	of	cardiac	
hypertrophy. N	=	21	Young,	21	Old	Control,	16	Old	SS-31,	15	Old	NMN,	14	Old	Combined.
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significantly (p	 <	 0.005)	 improved	 high	 work	 percent	 fractional	
shortening	in	Old	mice,	fully	restoring	it	to	Young	levels	(Figure	1b).
While	 our	 previous	 studies	 have	 shown	 that	 SS-31	 induces	 a	
partial effect on diastolic function after 4 weeks of treatment and 
appears	to	reach	its	peak	effect	at	8	weeks	(Chiao	et	al.,	2020),	it	was	
unknown on what timescale the cardiac functional improvements in-
duced	by	NMN	occur.	To	test	this,	Young	and	Old	mice	were	treated	
with	 NMN	 and	 tested	 at	 regular	 intervals	 to	 determine	 changes	
in	 their	 high	work	 percent	 fractional	 shortening	 (Figure	 1c).	 After	
10	 days	 of	 treatment,	Old	mice	 treated	with	NMN	 showed	 a	 sig-
nificant (p	<	0.05)	improvement	in	high	work	fractional	shortening,	
restoring	it	to	Young	levels.	This	remained	constant,	with	no	further	
enhancement	from	prolonged	treatment.	Young	fractional	shorten-
ing	was	unaffected	by	NMN	treatment.	Young	mice	were	also	given	
SS-31	to	determine	whether	there	was	any	effect	on	diastolic	func-
tion,	 but	 the	 Ea/Aa	 ratio	was	 not	 significantly	 changed	 after	 4	 or	
8	weeks	of	SS-31	treatment	(Figure	S3).	The	persistence	of	the	func-
tional	improvement	induced	by	NMN	treatment	was	also	examined.	
In	contrast	to	SS-31,	which	we	have	previously	shown	to	maintain	
half its functional effect 4 weeks after cessation of treatment (Chiao 
et	al.,	2020),	NMN's	effect	on	aged	hearts	is	more	transient.	After	
stopping	NMN	treatment,	high	work	fractional	shortening	remained	
the	same	one	day	later	but	then	declined	at	approximately	the	rate	it	
had	improved	after	starting	treatment,	matching	the	baseline	for	Old	
hearts	after	10	days	without	treatment	(Figure	S4).
Relative	 to	Young	mice,	Old	Control	mice	showed	a	significant	
(p	<	0.05)	increase	in	cardiac	hypertrophy,	measured	as	the	ratio	of	
heart	weight	 to	 tibia	 length	 (Figure	 1d).	 NMN	 and	 the	 Combined	
treatments appeared to reduce this hypertrophy and partially re-
store	heart	weight/tibia	length	to	the	Young	state,	but	SS-31	alone	
did not have a significant effect.
Mitochondrial function in isolated cardiomyocytes from Old 
Control	and	NMN-treated	hearts	was	assessed	by	Seahorse	assay	
(Agilent	Technologies,	Santa	Clara,	CA).	While	we	have	previously	
shown	by	this	method	that	SS-31	normalized	age-related	increases	
in	basal	respiration	and	proton	leak	(Chiao	et	al.,	2020),	NMN	treat-
ment	did	not	appear	to	have	any	such	effect,	as	mitochondrial	oxy-
gen consumption appeared unchanged from the Control group by all 
measures	(Figure	S5).
2.2  |  Metabolomic analyses of hearts reveal unique 
changes resulting from SS-31 and NMN treatments
Analysis	of	cardiac	metabolic	differences	at	 the	endpoint	of	 treat-
ment	was	completed	by	two	LC-MS/MS	methods:	(a)	a	focused	anal-
ysis	of	NAD-related	metabolites	and	(b)	a	general	screening	of	369	
common metabolites.
By	 the	 first	 method,	 the	 total	 NAD(H)	 pool	 of	 the	 heart	 ap-
peared	 to	decline	with	age	 (Figure	2a),	as	has	been	reported	else-
where	(Braidy	et	al.,	2011).	Neither	SS-31	nor	NMN	treatment	alone	
resulted	in	any	change	to	total	NAD(H).	However,	when	NMN	and	
SS-31	were	given	in	combination,	there	was	a	significant	(p	<	0.05)	
increase	 in	 NAD(H)	 levels.	 The	 ratio	 of	 NAD+	 to	 NADH	 did	 not	
change	significantly	in	any	of	the	groups.	NADP+ also did not show 
any	significant	changes	between	the	groups	(Figure	2b),	and	NADPH	
was	 undetectable	 by	 this	 assay.	 Of	 the	 assayed	 NAD	 precursors,	
only	nicotinamide	(NAM)	showed	a	difference	between	groups,	with	
a significant (p	<	0.02)	decrease	 in	 levels	between	Young	and	Old	
Control	hearts,	and	a	restoration	by	both	NMN	and	Combined	treat-
ments (p	<	0.05)	(Figure	2c).	NMN,	nicotinamide	riboside	(NR),	and	
nicotinic	acid	(NA)	also	showed	the	same	trend	of	a	decrease	with	
age	and	restoration	by	NMN	and	Combined	treatments	but	did	not	
individually	 reach	significance	 (Figure	2d–f).	Nicotinamide	adenine	
dinucleotide	(NAAD)	did	not	follow	this	trend	and	did	not	show	any	
significant	changes	(Figure	2g).
In	 the	 general	 targeted	 metabolomics	 assay,	 which	 primarily	
assessed metabolites involved in protein and carbohydrate energy 
metabolism,	26	metabolites	showed	significant	(FDR	<	0.1)	changes	
when	comparing	Young	to	Old	Control	mice	(Table	1).	None	of	the	
treatments appeared to have a significant effect on shifting the 
overall	metabolome	of	Old	hearts	back	toward	the	Young	state,	and	
each	showed	only	a	few	significant	(FDR	<	0.1)	changes.	Most	nota-
bly,	the	NMN	and	Combined	treatments	resulted	in	a	sharp	increase	
in	 1-methylnicotinamide	 (MNA)	 (FDR	<	 0.0001)	 in	Old	mice	 com-
pared	to	Young,	Old	Control,	and	Old	SS-31	mice	(Figure	3a).	SS-31	
treatment	 resulted	 in	 modest	 increases	 in	 xanthine	 and	 choline	
(FDR	<	0.1)	levels	(Figure	3b,c).	Intriguingly,	the	Combined	treatment	
did	not	recapitulate	the	SS-31-induced	changes	and	instead	showed	
similar	 levels	of	both	choline	and	xanthine	 to	 the	Old	Control	and	
Old	NMN	groups.	The	 full	 set	of	 comparisons	between	all	 groups	
can	 be	 found	 in	 the	 Appendix	 S1.	 We	 investigated	 whether	 the	
change	in	MNA	levels	could	be	due	to	a	difference	in	nicotinamide	
N-methyltransferase	(NNMT)	levels;	however,	this	enzyme	was	not	
detectable	in	any	mouse	hearts	by	Western	blot	(Figure	S6)	or	shot-
gun	proteomics	(data	not	shown).
Analysis	 of	 general	 trends	 in	 canonical	 pathways	 from	 this	
dataset was performed based on all changes p	<	0.05	 (unadjusted	
p-values)	 in	 Young	 relative	 to	 Old	 Control	 hearts	 using	 Ingenuity	
Pathway	Analysis	(Qiagen,	Hilden,	Germany).	This	revealed	that	the	
major	metabolic	pathways	being	affected	by	age	included	glycolysis,	
citrulline	 biosynthesis,	 phosphatidylcholine	 biosynthesis,	 and	 oth-
ers	 (Figure	3d).	Quantification	of	 relative	changes	 in	the	canonical	
pathways heatmap was split into metabolites that increased with age 
(Figure	3e)	and	those	that	decreased	with	age	(Figure	3f).	While	there	
were	suggestive	trends	toward	reversal	of	the	age-related	changes	
F I G U R E  2   Analysis	of	endpoint	NAD+-related	metabolite	levels.	Endpoint	(8	weeks	of	treatment)	levels	of	(a)	NAD(H),	(b)	NADP+,	(c)	
NAM,	(d)	NMN,	(e)	NR,	(f)	NA,	and	(g)	NAAD	in	mouse	hearts	as	measured	by	targeted	LC-MS/MS.	The	height	of	the	stacked	columns	in	(a)	
indicates	the	total	NAD+NADH	content.	The	significance	noted	is	based	on	these	total	values.	N	=	11	Young,	10	Old	Control,	11	Old	SS-31,	
11	Old	NMN,	8	Old	Combined.
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to	 these	pathways,	 treatment	effects	did	not	 reach	significance	 in	
the	quantification.	Mean	difference	plots	 for	each	comparison	are	
provided	in	the	supplemental	data	(Figure	S7).
2.3  |  Magnetic resonance spectroscopy probes 
dynamic metabolic shifts in vivo
31P-magnetic	 resonance	 spectroscopy	 (MRS)	 was	 applied	 at	 the	
treatment endpoint in order to probe how metabolites in the heart 
respond	 to	 a	 dobutamine-induced	 increase	 in	 cardiac	workload	 in	
vivo.	Image-Selected	In	Vivo	Spectroscopy	(ISIS)	was	used	to	collect	
data localized to the heart with minimal inclusion of surrounding tis-
sues.	A	representative	heart-localized	voxel	and	resulting	MRS	spec-
trum	from	this	technique	are	shown	in	Figure	4a.
The principle difference in the energetic response to the in-
creased heart rate was measured as the ratio of the peak areas of 
phosphocreatine	(PCr)	to	γ-ATP	(given	as	PCr/ATP;	Figure	4b).	This	
measurement provides an assessment of how effectively the heart 
can respond to increased work by determining the degree to which 
the	 high-energy	 phosphates	 stored	 in	 PCr	 are	 depleted	 from	 car-
diomyocytes	under	increased	demand	for	ATP.	While	Young	mouse	
hearts	showed	no	change	in	PCr/ATP	in	response	to	increased	work-
load,	Old	Control	mouse	hearts	had	a	significant	(p	<	0.05)	decrease	
in	PCr/ATP	following	dobutamine	injection,	indicating	a	diminished	
ability	of	 the	heart	 to	handle	 such	a	workload	with	age.	Although	
still	 showing	a	 slight	decrease	 in	PCr/ATP	at	 the	higher	workload,	
the	SS-31,	NMN,	and	Combined	treatments	all	appeared	to	mitigate	
the	age-related	change,	and	PCr/ATP	in	the	treated	groups	was	not	
significantly	different	from	the	Young	state	or	their	predobutamine	
baselines.
In order to analyze how less abundant metabolites in the heart 
respond	 to	 increased	 cardiac	 workload	 in	 these	 mice,	 peaks	 cor-
responding to chemical standards of α-ATP,	 UDP-glucose,	 NAD+,	
Metabolite
Fold change relative to old control
Young Old SS−31 Old NMN
Old 
combined
5-Aminovaleric	acid 2.09(0.38) 1.79(0.38) 1.76(0.38) 1.81(0.41)
Carnosine 2.00(0.15) 0.78(0.16) 0.84(0.16) 0.94(0.17)
N-Formylmethionine 1.93(0.32) 1.60(0.32) 1.62(0.33) 1.79(0.35)
Hypotaurine 1.92(0.21) 1.16(0.22) 1.23(0.22) 1.35(0.23)
Beta-alanine 1.78(0.15) 0.95(0.15) 1.21(0.15) 1.12(0.16)
Anserine 1.64(0.10) 0.80(0.11) 0.89(0.11) 0.82(0.11)
Adenine 1.56(0.16) 1.09(0.17) 1.03(0.17) 1.21(0.18)
Cholesterol sulfate 1.46(0.19) 1.14(0.19) 1.08(0.19) 1.11(0.20)
Ethylmalonic acid 1.39(0.18) 1.00(0.18) 1.29(0.18) 1.06(0.19)
5′-Methylthioadenosine 1.35(0.14) 1.00(0.14) 0.96(0.14) 1.05(0.15)
ADP 1.32(0.08) 1.07(0.08) 1.02(0.08) 1.02(0.09)
Citrulline 1.29(0.10) 1.01(0.10) 1.04(0.10) 1.13(0.11)
L-Glutamic	acid 1.20(0.10) 1.11(0.10) 0.98(0.10) 0.94(0.11)
Choline 1.14(0.06) 1.19(0.06) 0.99(0.06) 1.02(0.07)
L-Serine 0.81(0.10) 1.06(0.10) 0.90(0.10) 0.89(0.11)
Sedoheptulose	7-phosphate 0.77(0.13) 1.20(0.13) 0.93(0.13) 1.04(0.14)
3-Methylhistidine 0.65(0.16) 0.89(0.16) 0.97(0.16) 0.87(0.18)
Pipecolic acid 0.63(0.20) 0.97(0.20) 0.86(0.20) 0.90(0.21)
Dihydroxyacetone	
phosphate
0.59(0.14) 0.72(0.14) 0.93(0.14) 0.81(0.16)
Lactose/trehalose 0.55(0.25) 0.81(0.26) 0.99(0.26) 1.14(0.28)
Glyceraldehyde-3-phosphate 0.54(0.16) 0.71(0.16) 0.91(0.16) 0.78(0.17)
Erythrose	4-phosphate 0.50(0.28) 0.75(0.29) 0.91(0.29) 1.03(0.31)
Glucose-6-phosphate 0.49(0.29) 0.77(0.29) 0.93(0.29) 1.05(0.31)
Trimethyloxamine 0.47(0.31) 1.33(0.31) 1.14(0.31) 1.07(0.34)
Glucose-1,6-bisphosphate 0.40(0.32) 0.56(0.32) 0.90(0.32) 0.61(0.34)
L-Cystine 0.32(0.43) 0.85(0.43) 0.58(0.44) 0.62(0.47)
Values are untransformed fold changes with standard errors in parentheses. Bold numbers indicate 
significance	(FDR	<	0.1).	Ordered	by	fold	change.	Full	results	can	be	found	in	the	Appendix	S1.
TA B L E  1   Significant	age-related	
metabolomics changes in mouse hearts
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NADH,	 NADP+,	 and	 NADPH	 were	 fit	 to	 the	 experimental	 spec-
tra	 for	quantification	using	a	 custom	model	 in	OriginPro	 software	
(OriginLab,	 Northampton,	MA).	 An	 additional	 peak	 corresponding	
to	mitochondrial	NAD(P)H	was	also	fit	to	the	data,	based	upon	our	
prior	study	demonstrating	the	presence	of	this	peak	in	vivo,	which	
has	an	altered	chemical	shift	 relative	to	cytosolic	NAD(P)H	due	to	
the	 unique	 environment	 of	 the	 mitochondrial	 matrix	 (Conley,	 Ali,	
Flores,	 Jubrias,	&	Shankland,	 2016).	A	 representative	 fit	 of	 exper-
imental data using this model is shown in Figure 4c. To assess the 
performance	of	this	technique	for	analyzing	these	metabolites,	MRS	
results from Old Control mice prior to dobutamine injection were 
compared	with	those	from	the	general	metabolomics	screen,	which	
also	analyzed	NAD(P)(H)	and	UDP-glucose	(Figure	4d).	Relative	lev-
els	 (normalized	 to	mean	NAD+	 for	 comparison	across	methods)	of	
NAD+,	 NADH,	 and	 UDP-glucose	 determined	 by	 both	 techniques	
were	 remarkably	 similar,	 but	 there	 was	 a	 large	 discrepancy	 in	
NADP+	and	NADPH	levels,	which	were	much	higher	relatively	when	
measured	by	MRS.	This	is	unsurprising	given	the	known	issues	with	
extracting	 and	 preserving	 these	 metabolites	 from	 tissue	 samples	
(Lu,	Wang,	Chen,	Hui,	&	Rabinowitz,	 2018)	 and	 thus	may	 actually	
demonstrate	a	strength	of	the	in	vivo	MRS	method.	Mitochondrial	
NAD(P)H	cannot	be	distinguished	from	the	cytosol-localized	mole-
cules by the metabolomics method and thus was not included in the 
comparison.	Overall,	this	comparison	supports	the	relative	quantifi-
cation	of	these	metabolites	from	in	vivo	heart	MRS	spectra.
The	MRS	data	showed	a	trend	of	NAD+ remaining stable or de-
creasing	slightly	in	Young	hearts	with	higher	workload	but	increasing	
in Old Control hearts (p	=	0.066)	(Figure	4e).	SS-31	and	the	Combined	
treatment	appeared	to	reverse	this	age-related	change	in	NAD+ dy-
namics.	Conversely,	NMN	treatment	did	not	reverse	the	age-related	
change	and	the	increase	in	NAD+ at higher workload in these mice 
was significantly (p	<	0.05)	different	from	the	Young	state	at	higher	
workload.	 Mitochondrial	 NAD(P)H	 also	 showed	 changing	 dynam-
ics	with	drug	 treatment	 (Figure	4f).	While	Young	and	Old	Control	
F I G U R E  3   General	metabolomics	analysis	of	mouse	hearts.	Endpoint	(8	weeks	of	treatment)	levels	of	(a)	1-methylnicotinamide	(MNA),	
(b)	xanthine,	and	(c)	choline	as	measured	by	general	targeted	metabolomics.	N	=	12	Young,	10	Old	Control,	12	Old	SS-31,	11	Old	NMN,	8	Old	
Combined.	Means	are	calculated	from	postprocessed	values	and	are	not	log2-transformed.	(d)	Heatmap	of	metabolic	changes	in	the	top	20	
canonical pathways based on all changes with an unadjusted p	<	0.05	when	comparing	Young	to	Old	Control.	(e	and	f)	Quantification	of	the	
heatmap,	separated	into	metabolites	that	decreased	(e)	or	increased	(f)	with	age.
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hearts	 had	 a	 trend	 of	 slightly	 decreased	 mitochondrial	 NAD(P)H	
with	 the	 increased	heart	 rate,	SS-31	and	NMN-treated	hearts	 ap-
peared to reverse this trend (p	=	0.074	and	p	<	0.05,	respectively),	
as	these	treatments	increased	mitochondrial	NAD(P)H	in	response	
to	a	higher	workload.	Interestingly,	the	Combined	treatment	did	not	
recapitulate	 the	 individual	 results	 of	 SS-31	 and	NMN	and	 instead	
showed	mitochondrial	NAD(P)H	 levels	that	were	unchanged	when	
dobutamine was applied. Other metabolites did not show a signifi-
cant	difference	between	groups	with	increased	workload,	and	these	
results	are	presented	in	Figure	S8.
3  |  DISCUSSION
3.1  |  SS-31 and NMN improve different aspects of 
heart health
SS-31	and	NMN	treatments	distinctly	improve	diastolic	and	higher	
workload	 systolic	 function,	 respectively.	 Since	 giving	 the	 drugs	 in	
combination	conferred	both	diastolic	and	systolic	improvements,	but	
neither	prevented	nor	further	added	to	the	individual	improvements,	
the data imply that the drugs use two independent mechanisms to 
achieve	these	functional	benefits.	Furthermore,	since	the	drugs	only	
showed	an	effect	in	Old	hearts,	this	appears	to	be	a	true	rejuvena-
tion of heart function in both cases.
In	 this	cohort	of	mice,	we	found	that	NMN	and	the	Combined	
treatment	were	effective	at	reducing	age-related	hypertrophy	of	the	
heart	while	SS-31	alone	was	not.	However,	in	other	cohorts	of	mice	
we have previously observed a modest but significant reduction in 
hypertrophy	 following	SS-31	 treatment	 (Chiao	et	al.,	2020).	Given	
the small difference in magnitude between these new results and 
those	already	published,	we	believe	this	difference	is	primarily	based	
upon statistical variation and not the underlying biology.
NMN	appears	 to	have	a	much	more	acute	effect	on	 the	heart	
than	 SS-31.	While	 NMN	 achieves	 its	 peak	 functional	 effect	 after	
just	10	days	of	treatment,	we	have	previously	observed	that	SS-31	
treatment	takes	approximately	8	weeks	to	reach	its	peak	effect	on	
the	heart	 (Chiao	et	al.,	2020).	NMN's	effect	was	halved	by	6	days	
after	 treatment	 cessation	 and	 completely	 gone	 after	 10	 days,	
whereas	a	partial	SS-31	effect	persisted	for	several	weeks	after	ces-
sation	of	treatment	(Chiao	et	al.,	2020).	These	differing	timelines	fit	
with	 the	hypothesis	 that	SS-31	carries	out	 its	effects	by	 repairing	
F I G U R E  4  Magnetic	resonance	measurements	of	dynamic	mitochondrial	metabolism.	(a)	Representative	1H-magnetic	resonance	imaging	
of	mouse	chest	cavity,	heart	voxel	localization	for	ISIS,	and	resulting	31P	spectrum.	(b)	Change	in	PCr/ATP	ratio	after	injection	of	dobutamine.	
N	=	11	Young,	11	Old	Control,	11	Old	SS-31,	13	Old	NMN,	10	Old	Combined.	(c)	Representative	image	of	the	automated	fitting	model.	(d)	
Comparison	of	MRS	and	metabolomics	Old	Control	results.	N	=	11	MRS,	10	metabolomics.	(e	and	f)	Change	in	(e)	NAD+	and	(f)	mitochondrial	
NAD(P)H	after	injection	of	dobutamine.	N	=	11	Young,	10	Old	Control,	9	Old	SS-31,	11	Old	NMN,	10	Old	Combined.
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mitochondria	efficiency	and	reducing	oxidative	stress,	followed	by	
myocardial	remodeling	(Chiao	et	al.,	2020),	whereas	NMN	primarily	
works	by	boosting	NAD(H)	biosynthesis	and	 thus	enhancing	myo-
cardial	energetic	supply	via	oxidative	phosphorylation.
Consistent	with	these	proposed	mechanisms,	we	did	not	detect	
any	difference	in	mitochondrial	coupling/efficiency	in	the	Seahorse	
assay	with	unstimulated	cardiomyocytes	isolated	from	NMN-treated	
hearts.	 This	 is	 in	 clear	 contrast	 to	 SS-31,	 which	 improved	 proton	
leak	 and	 respiratory	 control	 ratio	 in	 the	 same	 assay	 (Zhang	 et	 al.,	
2020).	We	believe	this	is	consistent	with	mitochondrial	remodeling	
by	SS-31	that	does	not	occur	following	NMN	treatment.	However,	
this	does	not	mean	that	NMN	does	not	have	any	effect	on	the	mito-
chondria,	as	discussed	below.
3.2  |  Metabolic crosstalk between SS-31 and 
NMN and the fate of NAD+
The	observation	that	NAM	and	MNA	concentrations	increased	after	
NMN	treatment	is	unsurprising,	given	that	both	are	steps	along	the	
breakdown	 pathway	 of	 NAD+	 (Bender,	 2003).	 Thus,	 the	 increase	
in	 both	metabolites	 is	 an	 expected	 result	 of	 increased	NAD+ bio-
synthesis	and	greater	turnover	of	NAD+ from its use as an enzyme 
cofactor,	 primarily	 for	 sirtuin	 deacetylases	 and	 poly	 ADP-ribose	
polymerases	(PARPs)	(Pillai,	Isbatan,	Imai,	&	Gupta,	2005).	This	en-
hanced	 turnover	 of	NAD+	may	 explain	why	NMN	 treatment	 does	
not	significantly	increase	resting	NAD(H)	levels,	as	noted	here	and	
in	previous	 study	 (Mills	et	 al.,	2016).	However,	 it	 is	 less	 clear	why	
NMN	and	SS-31	given	in	combination	did	significantly	increase	the	
NAD(H)	pool	when	neither	drug	alone	did.	This	would	appear	to	in-
dicate	a	synergistic	effect	of	the	drugs.	One	plausible	explanation	is	
that	SS-31's	demonstrated	reduction	of	oxidative	stress	(Chiao	et	al.,	
2020;	Hou	et	al.,	2016)	results	in	less	PARP	activation	and	therefore	
less	NAD+	breakdown,	allowing	it	to	accumulate	to	higher	levels	in	
the cell.
Since	NNMT,	 the	enzyme	that	converts	NAM	to	MNA	and	re-
moves	 it	 from	 reentering	 the	NAD+ salvage pathway of synthesis 
(Bockwoldt	et	al.,	2019),	was	at	undetectable	levels	in	the	heart,	 if	
present	at	all,	conversion	to	MNA	is	likely	occurring	elsewhere	in	the	
mice,	with	the	MNA	found	in	the	heart	having	entered	from	the	cir-
culation.	One	concern	with	increased	MNA	synthesis	is	the	potential	
for	depletion	of	methyl	donors	in	the	cell	(Pissios,	2017).	Neither	the	
NMN	or	Combined	treatment	group	showed	a	significant	decrease	
in	S-adenosyl	methionine	(Appendix	S1),	the	major	methyl	donor	of	
the	cell	and	the	one	utilized	for	MNA	synthesis,	so	it	does	not	appear	
that	methyl	donors	were	depleted	 to	 a	 significant	 level.	However,	
enhanced	usage	of	S-adenosyl	methionine	 likely	does	explain	why	
the	slight	increase	in	choline	induced	by	SS-31	treatment	was	pre-
vented	by	simultaneous	treatment	with	NMN,	since	choline	is	used	
to	produce	S-adenosyl	methionine	(Zeisel	&	Corbin,	2012).
Why	SS-31	treatment	causes	an	increase	in	xanthine	and	choline,	
and	why	 the	 addition	 of	NMN	prevents	 the	 accumulation	 of	 xan-
thine,	is	less	clear.	In	the	case	of	choline,	the	SS-31	effect	appears	
to	be	a	restoration	of	an	age-related	loss	in	the	metabolite	and	could	
be	due	 to	 changes	 in	 phospholipid	production	 induced	by	 SS-31's	
remodeling	of	 the	mitochondrial	 inner	membrane.	Conversely,	 the	
increase	 in	 xanthine	 is	 a	 further	movement	 away	 from	 the	Young	
state	and	the	reason	for	this	change	is	unclear.	Adenine	is	one	source	
of	 xanthine,	 by	 its	 deamination	 to	 hypoxanthine	 (Harrison,	 2002),	
and	more	adenine	is	expected	to	be	used	for	NAD+ synthesis with 
the	 addition	 of	NMN,	 providing	 one	 potential	 explanation	 for	 the	
NMN	treatment	preventing	the	SS-31-induced	increase	in	xanthine.	
Overall,	the	differences	in	xanthine	and	choline	appear	to	be	minor	
metabolic	consequences	of	the	drugs	but	seemingly	unrelated	to	the	
functional improvements in the heart.
Although	a	wide	selection	of	metabolites	was	screened,	there	are	
more that could be assessed to provide valuable information on the 
aging	heart	and	the	effect	of	these	drugs.	Lipid	metabolism	is	an	area	
we believe demands further investigation in future studies with this 
model system. Measurement of metabolic enzyme levels and activity 
could	also	provide	valuable	information	on	the	mechanisms	of	age-re-
lated dysfunction and the restorative properties of these drugs.
3.3  |  SS-31 and NMN restore PCr/ATP dynamics 
in the heart
In	this	study,	we	applied	 in	vivo	MRS	to	demonstrate	that	there	 is	
an	age-related	shift	 in	the	dynamics	of	PCr/ATP	in	response	to	 in-
creased cardiac workload. Old Control hearts showed a drop in PCr/
ATP	with	a	higher	workload,	whereas	this	parameter	remained	sta-
ble	in	Young	hearts.	From	this,	we	can	conclude	that	mitochondria	
in Old hearts are less able to meet the energetic demand of a high 
work	state	and	PCr	decreases	as	a	consequence	of	its	high-energy	
phosphates	being	utilized	to	maintain	ATP	status	in	myofibrils	faster	
than	oxidative	phosphorylation	can	restore	it.	The	attenuation	of	the	
effect	of	age	on	 the	PCr/ATP	dynamics	by	SS-31	and	NMN	treat-
ment,	both	individually	and	in	combination,	suggests	that	both	drugs	
improve the ability of cardiac mitochondria to meet the metabolic 
demand of the increased workload.
3.4  |  Proposed model of dynamic mitochondrial 
metabolism changes
While	 limited	by	signal	 to	noise	and	high	variance,	 the	novel	MRS	
method	 that	we	describe	here	presents	an	exciting	new	means	 to	
analyze	metabolic	changes	in	response	to	a	stimulus	in	live	mice.	We	
believe	 that	 the	 mitochondrial	 NAD(P)H	 peak	 we	 have	 described	
consists	primarily	of	NADH	based	on	its	dynamic	behavior	here	and	
in	our	prior	study	in	which	it	was	first	described	(Conley	et	al.,	2016),	
although	we	are	unable	to	definitively	say	to	what	degree	NADPH	
contributes to the peak. Taking all of the above results into consid-
eration,	we	propose	the	following	model	to	contextualize	the	differ-
ences in metabolic shifts seen between the mouse groups with the 
increase in cardiac workload.
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Young	 hearts	 have	 a	 sufficient	 NAD(H)	 pool	 and	 undamaged	
mitochondria,	which	 provide	 them	with	 adequate	ATP	production	
capacity	to	meet	a	higher	workload.	As	a	result,	NAD+ and PCr do 
not	show	any	significant	shifts	from	increasing	workload,	while	mi-
tochondrial	NAD(P)H	trends	toward	a	slight	decrease	due	to	greater	
utilization.	Old	Control	 hearts	have	a	diminished	NAD(H)	pool,	 so	
higher	workload	 places	 a	 greater	 strain	 on	 the	mitochondrial	ATP	
production	capacity,	as	evidenced	by	accumulating	NAD+,	decreas-
ing	PCr,	and	reduced	high	work	systolic	function.
SS-31	in	Old	hearts	appeared	to	improve	the	efficiency	of	ATP	
production	in	the	mitochondria,	as	 it	normalized	the	shifts	 in	PCr	
and	NAD+	that	resulted	from	increasing	the	cardiac	workload.	A	rea-
son	for	this	might	be	that	mitochondrial	NAD(P)H	showed	a	reverse	
in	the	direction	of	change	with	increasing	workload	following	SS-31	
treatment,	 indicating	that	the	supply-demand	matching	of	NADH	
production	 was	 improved,	 with	 supply	 now	 outpacing	 demand	
rather than lagging behind. This implies a potential improvement in 
the	efficiency	of	the	tricarboxylic	acid	(TCA)	cycle.	Although	several	
TCA	cycle	intermediates	were	evaluated	by	the	general	metabolo-
mics	screen,	which	did	not	show	differences	resulting	from	SS-31	
treatment	 (Appendix	 S1),	 this	 does	 not	 rule	 out	 the	 involvement	
of	 the	 TCA	 cycle	 since	 these	measurements	were	 only	 collected	
from	tissue	taken	at	rest.	We	have	also	recently	demonstrated	that	
there	is	a	direct	interaction	between	SS-31	and	TCA	cycle	enzymes	
involved	 in	 alpha-ketoglutarate	metabolism	 (Chavez	 et	 al.,	 2019).	
Other	 reasons	 why	 ATP	 production	 may	 be	 enhanced	 by	 SS-31	
lie in its direct effects on the mitochondrial inner membrane and 
inner	 membrane	 proteins.	 We	 have	 recently	 demonstrated	 that	
SS-31	 is	 highly	 effective	 at	 preventing	 an	 age-associated	 excess	
protein	 leak	across	the	mitochondrial	 inner	membrane,	which	ap-
pears	to	be	mediated	by	the	adenine	nucleotide	translocase	(Zhang	
et	al.,	2020).	Reduced	production	of	reactive	oxygen	species,	which	
otherwise cause damage to mitochondrial proteins and consume 
NADPH	 through	 antioxidant	 regeneration,	 also	occurs	 and	 is	 an-
other	 likely	mechanism	 for	 the	 improved	 efficiency	 (Chiao	 et	 al.,	
2020).	However,	these	improvements	are	apparently	not	sufficient	
for	SS-31	to	restore	higher	work	systolic	function.
NMN	also	normalized	PCr	 levels	under	 the	higher	workload	 in	
Old	 hearts,	 but	 by	 a	 seemingly	 different	 mechanism	 than	 SS-31.	
NMN-treated	hearts	were	 the	only	group	 to	show	a	simultaneous	
increase	 in	 both	 NAD+	 and	mitochondrial	 NAD(P)H	 content.	 This	
could	 indicate	 that	 NMN-treated	 hearts	 responded	 to	 increased	
workload	 by	 rapidly	 increasing	 the	 synthesis	 of	NAD+ in order to 
raise	mitochondrial	NAD(H)	levels	and	provide	a	higher	capacity	for	
work in situ. This seemingly improved capacity allowed these hearts 
to	match	the	Young	state	in	high	work	systolic	function.
The Combined treatment in Old hearts appeared to best recapit-
ulate	the	Young	state.	This	group	did	not	show	any	significant	shifts	
in	PCr,	NAD+,	or	mitochondrial	NAD(P)H	following	 the	 increase	 in	
workload,	which	we	believe	 to	be	due	 to	 the	higher	energetic	 ca-
pacity	afforded	by	the	restoration	of	resting	NAD(H)	 levels.	These	
hearts	matched	the	high	work	systolic	function	of	the	Young	state,	
while	also	exhibiting	 improved	diastolic	function.	Thus,	the	combi-
nation	of	SS-31	and	NMN,	which	together	appear	to	 increase	fuel	
supply	and	coupling	efficiency	while	limiting	excess	oxidative	stress,	
provides a synergistic improvement in energetic capacity so that 
supply can fully meet demand.
3.5  |  Mechanisms of diastolic improvement by SS-
31
It is less clear whether the metabolic changes described above are 
directly responsible for the improvement in diastolic function result-
ing	from	SS-31	treatment.	Metabolic	changes	certainly	do	play	a	role	
in	diastolic	dysfunction,	as	it	is	well	established	that	ADP	levels	have	
a	regulatory	role	in	sarcomere	stiffness	with	higher	ADP	inhibiting	
relaxation	and	 increasing	diastolic	 stiffness	 (Sequeira	et	al.,	2015).	
The	previously	reported	effects	of	age	and	SS-31	on	mitochondrial	
coupling	in	cardiomyocytes	(Zhang	et	al.,	2020)	are	consistent	with	
a	role	for	altered	ADP	levels	in	the	changes	in	diastolic	function	re-
ported	here.	However,	we	did	not	detect	any	significant	changes	in	
ATP	or	ADP	at	rest	in	Old	hearts	treated	with	SS-31	in	our	metabo-
lomics	analysis	(Appendix	S1).	Furthermore,	we	found	by	MRS	that	
PCr/ATP	at	rest	was	unaltered	by	age	or	SS-31	(Figure	S10),	also	in-
dicating	a	 lack	of	difference	 in	resting	ADP	 levels.	 In	addition,	 the	
effects	on	SS-31	mitochondrial	coupling	we	have	reported	appear	
to	be	rapid	onset,	while	the	improvements	in	diastolic	dysfunction	
require	longer	term	treatment.	An	alternative	mechanism,	for	which	
we	have	previously	published	direct	evidence	(Chiao	et	al.,	2020),	is	
the	effect	of	SS-31	on	post-translational	modification	of	myofibrillar	
contractile	proteins.	In	particular,	SS-31	greatly	reduced	age-related	
increases	in	the	oxidation	state	of	the	proteome,	including	contrac-
tile	proteins,	and	restored	the	phosphorylation	levels	of	the	sarco-
meric	protein	myosin-binding	protein	C,	cardiac-type	(cMyBP-C)	to	
the	young	state.	These	changes	are	consistent	with	improved	relaxa-
tion	of	the	cardiac	sarcomere,	a	critical	aspect	of	diastolic	function	
(Gilda	&	Gomes,	2017;	McNamara,	Singh,	&	Sadayappan,	2019).
3.6  |  Conclusions
By	testing	SS-31	and	NMN	together	in	mice,	we	were	able	to	pro-
vide new insight into the effects and mechanisms of each drug in the 
heart.	Excitingly,	this	work	shows	that	NMN	and	SS-31	can	be	given	
in combination to rejuvenate both diastolic and systolic aspects of 
ventricular	function,	boost	NAD(H)	content	better	than	NMN	given	
alone,	and	stabilize	mitochondrial	NAD(H)	dynamics.	These	results	
may have strong clinical relevance and imply that synergistic treat-
ment with the two drugs in combination may be more effective at 
treating	age-related	heart	dysfunction	than	either	given	alone.	This	
is also an illustration that complimentary use of appropriate drug 
combinations may become a more general model for achieving opti-
mal	healthspan	extension.
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4  |  E XPERIMENTAL PROCEDURES
4.1  |  Animal use and care
All	mice	used	in	this	study	were	males	of	the	C57BL/6	strain.	Young	
and	Old	mice	were	obtained	 from	 the	National	 Institute	on	Aging	
Charles	River	 colony	 and	 further	 aged	 to	5–6	 and	24	months,	 re-
spectively,	 before	 starting	 the	 study.	Mice	 were	 kept	 under	 diur-
nal conditions with ad libitum food and water. Mice were housed 
at	20°C	under	diurnal	conditions	in	an	AAALAC-accredited	facility	
under	 Institutional	 Animal	 Care	 and	 Use	 Committee	 supervision	
with ad libitum access to food and water. Old mice were randomly 
assigned	to	Control,	SS-31,	NMN,	or	Combined	treatment	groups.
4.2  |  Drug administration and treatment groups
SS-31	was	provided	by	Stealth	BioTherapeutics	(Newton,	MA)	and	
administered at a 3 mg/kg body weight/day dosage through osmotic 
minipumps	 (ALZET,	Cupertino,	CA)	 implanted	 surgically	under	 the	
skin on the left dorsal side of the mice. Pumps were modified to 
replace	 the	metal	 stem	with	PEEK	 tubing,	 according	 to	 the	manu-
facturer's	 instructions,	 for	 compatibility	 with	 magnetic	 resonance	
spectroscopy.	After	4	weeks,	 the	original	minipump	was	surgically	
removed	and	a	new	minipump	was	implanted	to	continue	the	SS-31	
administration for another 4 weeks.
NMN	 was	 obtained	 from	 the	 Imai	 laboratory	 (Washington	
University	 in	 St.	 Louis,	MO)	 and	 administered	 through	 ad	 libitum	
drinking water with a concentration based on each cage's measured 
water	consumption	rate	and	mean	mouse	body	weight	to	approxi-
mate	a	300	mg/kg	body	weight/day	dose.	NMN	water	was	the	only	
source of hydration given to these mice and was replaced every 
3–7	days	based	upon	prior	tests	showing	that	 it	remains	stable	 in	
water	at	room	temperature	for	at	least	1	week	(Mills	et	al.,	2016).
Combined	 treatment	 mice	 received	 SS-31	 through	minipumps	
while	simultaneously	receiving	NMN	water	as	their	exclusive	source	
of hydration as described above.
Initially,	two	different	controls	groups	were	used:	mice	with	os-
motic	minipumps	containing	only	saline	as	a	control	for	SS-31	and	
mice without minipumps receiving standard water as a control for 
NMN.	However,	an	analysis	of	functional	and	MRS	results	revealed	
that there were no significant differences between these two con-
trol	groups	(Figure	S9).	Thus,	the	two	control	groups	were	integrated	
into a single control for all treatment conditions.
4.3  |  Echocardiography
Mice	 were	 anesthetized	 by	 0.75%–2%	 isoflurane,	 and	 echocardi-
ography	 was	 performed	 using	 a	 Siemens	 Acuson	 CV-70	 (Munich,	
Germany)	equipped	with	a	13	MHz	probe.	Heat	support	and	heart	
rate monitoring were provided throughout the procedure with 
mouse	heart	rates	being	maintained	in	the	range	of	450–550	bpm	at	
the	low	work	state.	Analysis	of	systolic	function	included	an	injec-
tion of 3 µg/g body weight dobutamine in order to induce a higher 
cardiac	workload	 and	 analyze	maximal	 function.	High	work	 echo-
cardiography was performed once the heart rate increased at least 
100 bpm and remained stable.
4.4  |  Euthanasia and tissue handling
Mice were euthanized by live cervical dislocation. Hearts were im-
mediately	removed,	flushed	with	PBS	to	remove	blood,	and	weighed.	
A	2-mm	section	was	removed	from	the	ventricles	for	histology,	and	
the remaining tissue was cut into ~2 mm3	chunks	and	snap-frozen	in	
liquid	N2 to store for further processing. Frozen tissue was mechani-
cally	lysed	into	a	fine	powder	using	a	Tissuelyser	II	(Qiagen)	prior	to	
preparation	for	LC-MS/MS-based	measurements.
4.5  |  Targeted NAD+ metabolomics
Levels	of	NAD+,	NADH,	NADP+,	NADPH,	NA,	NAAD,	NAM,	NR,	and	
NMN	at	treatment	endpoints	were	measured	by	Ultra	Performance	
Liquid	 Chromatography	 coupled	with	Mass	 Spectrometry	 as	 previ-
ously	described	(Trammell	&	Brenner,	2013),	with	some	modifications.	
Under	CO2	vapor,	lysed	tissue	was	dissolved	in	chilled	buffered	meth-
anol	solution	(75%	methanol,	25%	10	mM	HEPES	pH	7.8)	spiked	with	
stable	isotope-labeled	internal	standards	of	NAD+	and	NADH	for	nor-
malization,	and	brought	to	a	final	concentration	of	250	mg/ml.	Samples	
were	then	spun	down	repeatedly	at	16,000	g for 10 min and trans-
ferred to new tubes until no pellet formed. Pellets were saved for pro-
tein	quantification	as	an	additional	normalization	step.	Supernatants	
were	filtered	using	4-mm	and	0.22-µM	syringe	filters	(MilliporeSigma,	
Burlington,	MA).	5	µl	of	 the	extract	was	separated	on	a	BEHAmide	
column	(Waters,	Milford	MA)	using	an	Acquity	UPLC	(Waters)	and	an-
alyzed	with	a	Xevo	TQ	(Waters)	in	multiple	reaction	monitoring	mode	
(MRM).	LC	solvents	were	A:	H2O with 10 mM ammonium acetate and 
0.4%	NH4OH;	and	B:	95:5	acetonitrile	H2O with 10 mM ammonium 
acetate	and	0.4%	NH4OH	for	all	metabolites.	Samples	were	run	along-
side	an	external	standard	curve	for	quantification.
4.6  |  General targeted metabolomics
Heart tissue samples were homogenized in water and methanol with 
spiked	stable	isotopes	as	internal	QC	standards.	Samples	were	puri-
fied	by	pelleting	proteins,	drying	of	the	solution	via	Speedvac	(Thermo	
Fisher	Scientific),	and	reconstituting	in	HILIC	solvent.	Protein	pellets	
were	analyzed	by	BCA	(Thermo	Fisher	Scientific)	as	a	normalization	
step.	LC-MS/MS-based	metabolomics	targeting	a	list	of	369	metabo-
lites	was	performed	on	a	system	consisting	of	Shimadzu	Nexera	XR	
LC-20AD	pumps	(Kyoto,	Japan)	coupled	to	a	Sciex	(Framingham,	MA)	
6500+	triple	quadrupole	spectrometer	operating	in	scheduled	MRM	
detection	mode	through	the	Sciex	Analyst	1.6.3	software,	as	described	
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elsewhere	(Nagana	Gowda,	Djukovic,	Bettcher,	Gu,	&	Raftery,	2018).	
The	system	includes	a	dual-column	setup	with	dedicated	columns	for	
positive ionization mode and negative ionization mode. Metabolite 
concentrations	were	quantified	using	Sciex	MultiQuant	3.0.2	software.
Analysis	of	the	dataset	was	performed	using	R	(version	3.6.0).	In	
order	to	remove	the	systematic	variation	between	samples,	we	per-
formed	a	Cyclic	LOESS	normalization,	which	had	good	performance	
using	a	MS	benchmark	dataset	(Li	et	al.,	2017).	This	normalization	
step	is	implemented	using	the	limma	R	package	(Ritchie	et	al.,	2015).	
Missing values are known to be a problematic issue for mass spec-
trometry-based	data.	Previous	studies	have	summarized	the	three	
missing	value	mechanisms	in	terms	of	MS-based	data	(Lazar,	Gatto,	
Ferro,	Bruley,	&	Burger,	2016;	Wei	et	al.,	2018):	Missing	Completely	
At	 Random	 (MCAR),	 which	 corresponds	 to	 the	 combination	 and	
propagation of multiple minor errors or stochastic fluctuations. 
Each	missing	value	 cannot	be	directly	explained	by	 the	nature	of	
the	feature	or	by	its	measured	intensity.	Missing	At	Random	(MAR)	
assumes the possibility of a variable being missing is determined 
by	other	observed	variables,	 for	 example,	 inaccurate	peak	detec-
tion.	 Missing	 Not	 At	 Random	 (MNAR)	 corresponds	 to	 censored	
missing values caused by compound abundances that are below 
the	limits	of	quantification	(LOQ),	a.k.a.	left-censored	data.	For	the	
metabolomics	data,	the	missing	value	mechanism	is	believed	to	be	
MNAR.	All	the	metabolites	with	>40%	missingness	were	excluded,	
and a total of 191 metabolites were included in the imputation step 
(roughly	0.9%	of	the	data	is	missing	values	after	filtering).	We	used	
a	quantile	regression	approach	for	the	imputation	of	left-censored	
missing	data	(QRILC),	which	has	been	suggested	as	the	favored	im-
putation	method	 for	 left-censored	MNAR	data	 (Wei	et	al.,	2018).	
Briefly,	 QRILC	 performs	 imputation	 by	 replacing	 missing	 values	
with random draws from a truncated distribution with parameters 
estimated	 using	 quantile	 regression.	 This	was	 implemented	 using	
the	 imputeLCMD	R	package.	 Imputation	was	performed	after	the	
cyclic	LOESS	normalization.	We	fit	a	linear	model	to	the	normalized	
and imputed metabolomic data using the Bioconductor limma pack-
age while adjusting the preparation batch and protein concentra-
tion as covariates in our model. The limma package uses empirical 
Bayes	moderated	 statistics,	which	 improves	power	by	 ‘borrowing	
strength’ between metabolites in order to moderate the residual 
variance	(Smyth,	2004).	Sample	size	for	each	group	after	removing	
outliers	was	 Young	 =	 12,	Old	 Control	 =	 10,	Old	NMN	=	 11,	Old	
SS-31	=	12,	Old	Combined	=	8.	False	discovery	rate	(FDR)	was	lim-
ited	to	10%	using	the	Benjamini–Hochberg	method.
Heatmap generation was performed in R using the “heatmap” 
function	 to	create	a	 row-scaled	 image	based	upon	 the	 top	20	sig-
nificantly	altered	canonical	pathways	 in	the	Young	vs.	Old	Control	
comparison	as	determined	by	IPA	(Qiagen).
4.7  |  31P-magnetic resonance spectroscopy
Magnetic resonance spectroscopy was performed on live mice 
using	 a	4.7	Tesla	 instrument	operated	by	 the	Translational	Center	
for	Metabolic	Imaging	at	the	University	of	Washington.	Mice	were	
placed into a custom apparatus with coils for both 1H and 31P	NMR	
and	anesthetized	minimally	via	nose	cone	with	0.75%–1.5%	isoflu-
rane.	Heart	rate,	respiratory	rate,	and	temperature	were	monitored	
using	 a	 Model	 1030	 Monitoring	 &	 Gating	 System	 (Small	 Animal	
Instruments,	 Inc.,	 Stony	 Brook,	 NY).	 Anesthesia	 was	 adjusted	 as	
needed to maintain respiratory rate at 100–130 bpm. Temperature 
was also adjusted as needed to keep mice at a body temperature 
of	37°C.	Mice	were	equipped	with	an	intraperitoneal	catheter	con-
nected to a line of dobutamine to allow for remote injection without 
altering the position of the mouse.
Triggered,	 multi-slice,	 gradient	 echo,	 1H-magnetic	 resonance	
images	were	acquired	(TR	=	160	ms,	TE	=	4	ms,	with	a	2	mm	slice	
thickness)	to	place	a	voxel	isolating	the	heart	for	31P	ISIS	(Ordidge,	
Connelly,	&	Lohman,	1986).	31P	ISIS	spectra	(TR	=	3	s)	were	the	re-
sult	of	96	averages	(acquiring	a	total	of	768	acquisitions)	using	2	ms	
hyperbolic	secant	180o	pulses	during	localization,	but	a	nominal	90°	
square	 (50	μs),	 non-selective	 pulse	 for	 readout.	 Typical	 voxel	 size	
was	~0.8	cm3 to sample the entire heart. Data were collected over 
a	38-min	acquisition	with	gating	based	upon	heart	 rate	and	 respi-
ratory rate to ensure the position of the heart was constant across 
measurements.	 Following	 the	 first	 acquisition,	mice	were	 injected	
with	5	µg/g	dobutamine.	The	second	acquisition	was	started	once	
the elevated heart rate became stable.
Manual	 phase	 adjustment	 of	 the	 spectra,	 alignment	 of	 PCr	 to	
−2.54	ppm,	and	quantification	of	PCr	and	γ-ATP	integrals	were	per-
formed	 in	 TopSpin	 (Bruker,	 Billerica,	 MA).	 Baseline	 correction	 of	
spectra	was	performed	using	Mnova	software	(MestreLab	Research,	
S.L.,	Santiago	de	Compostela,	Spain).
OriginPro	 software	 (OriginLab	 Corporation)	 was	 used	 to	
model the fitting of α-ATP,	NAD+,	 cytosolic	NADH,	NADP+,	 cyto-
solic	NADPH,	UDP-glucose,	 and	mitochondrial	NAD(P)H	peaks	 to	
the	 baseline-corrected	 experimental	 spectra	 for	 quantification	 of	
these	molecules.	Lorentzian	peaks	were	positioned	and	modeled	as	
singlets,	 doublets,	 or	 quartets	based	upon	analysis	 chemical	 stan-
dards	on	the	instrument	under	physiological	(12	mM	Mg2+,	pH	7.4)	
conditions	 (Figure	 S10).	 Peak	 width	 was	 variable	 across	 different	
experimental	 spectra	but	was	kept	 consistent	 for	NAD+,	 cytosolic	
NADH,	 NADP+,	 cytosolic	 NADPH,	 and	 UDP-glucose	 within	 each	
fit.	Mitochondrial	NAD(P)H	peak	width	was	allowed	to	vary	within	
1.5-	to	threefold	that	of	the	other	peaks.	Best	fits	were	generated	
automatically	based	on	this	model,	with	no	manual	adjustment	used.	
Peaks	were	integrated	automatically,	and	non-ATP	metabolites	were	
normalized to α-ATP	 for	 relative	 quantification.	 OriginPro	macros	
are	available	upon	request.
4.8  |  Statistical analysis
Statistical	 analysis	of	 large-scale	metabolomic	data	 is	described	 in	
the above section. Other statistical analyses were performed using 
Prism	(GraphPad	Software,	San	Diego,	CA).	One-way	ANOVAs	were	
used	for	measurements	with	a	single	time	point	or	state	per	group,	
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and	two-way	ANOVAs	were	used	to	compare	measurements	with	
multiple	 time	points	 or	 states	 for	 each	 group.	One-sample	 t	 tests	
were used to determine whether delta means were significantly dif-
ferent	from	0.	All	results	are	plotted	as	means	±	SEM.
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